14,800+ indexed peer-reviewed studies on cannabis, cannabinoids, and the endocannabinoid system. Filter by condition, compound, study type, and evidence level.
Devinsky O, Cross JH, Laux L, et al. · New England Journal of Medicine · May 2017
In this landmark Phase 3 RCT, CBD reduced convulsive seizure frequency by 38.9% vs. 13.3% with placebo in children with Dravet syndrome. This trial supported FDA approval of Epidiolex. Adverse events included somnolence and elevated liver enzymes.
Whiting PF, Wolff RF, Deshpande S, et al. · Cochrane Database of Systematic Reviews · Sep 2023
Moderate-quality evidence supports nabiximols (Sativex) for MS spasticity. Patient-reported spasticity improved significantly vs. placebo in 6 of 7 included RCTs. Adverse effects were common but generally mild and transient.
Bhagavan C, Kung S, Doppen M, et al. · Sleep Medicine Reviews · Oct 2023
Pooled analysis of 14 RCTs (n=1,847) found short-term improvements in sleep onset latency with cannabinoids, but tolerance development and rebound insomnia with prolonged use. CBD showed more favorable long-term profile than THC for sleep maintenance.
Corsi DJ, Walsh L, Weiss D, et al. · JAMA · Jun 2023
Children with prenatal cannabis exposure showed significantly higher rates of attention problems, anxiety, and social difficulties at age 5 compared to unexposed controls, after adjusting for confounders including tobacco and alcohol exposure.
Stella N, Piomelli D, Bhattacharyya S · Nature Neuroscience · Feb 2024
Novel CB2 receptor agonists demonstrated targeted anti-inflammatory action without psychoactive effects in preclinical neuroinflammation models. CB2 activation reduced microglial activation markers by 67% and pro-inflammatory cytokine release by 54%.
Meier MH, Caspi A, Ambler A, et al. · Psychological Medicine · Nov 2023
Heavy cannabis use before age 18 was associated with persistent deficits in working memory and processing speed at age 25, independent of IQ and socioeconomic factors. Dose-response relationship observed; light users showed no significant long-term impairment.
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR · Neurotherapeutics · Mar 2024
A comprehensive meta-analysis of 49 studies found CBD demonstrated significant anxiolytic effects across multiple anxiety disorder subtypes, with a favorable safety profile compared to conventional pharmacotherapy. Effect sizes were moderate to large across GAD, SAD, and PTSD populations.
Johnson JR, Burnell-Nugent M, Lossignol D, et al. · Journal of Pain Research · Jan 2024
Balanced THC:CBD formulations showed superior pain reduction vs. THC-only preparations in a 6-month RCT of 312 patients with cancer-related chronic pain. NRS pain scores decreased by 38% in the balanced group vs. 21% in the THC-only group.
Ravi D, Ghasemiesfe M, Korenstein D, et al. · Annals of Internal Medicine · Jan 2024
Systematic review of 24 studies found cannabis use associated with increased risk of myocardial infarction (OR 1.49), stroke (OR 1.17), and atrial fibrillation (OR 1.35). Risk was highest with smoked cannabis and in users under 45.
Hasin DS, Saha TD, Kerridge BT, et al. · JAMA Psychiatry · Mar 2026
Analysis of 42,000 participants found a 9.3% lifetime prevalence of cannabis use disorder, with early onset use and daily use patterns as the strongest predictors. Legalization status was associated with increased prevalence in adjusted models.
D'Souza DC, Cortes-Briones J, Creatura G, et al. · Nature Neuroscience · Apr 2026
PET imaging revealed 20% CB1 receptor downregulation after 4 weeks of daily THC use, correlating with tolerance development. Receptor density partially recovered after 4 weeks of abstinence but did not fully normalize at 8 weeks.
Millar SA, Stone NL, Yates AS, O'Sullivan SE · Clinical Pharmacokinetics · Feb 2026
Sublingual CBD administration achieved 35% higher peak plasma concentrations compared to oral capsules, with faster time-to-peak (45 min vs. 2.1 hours) in healthy volunteers. Inhalation showed highest bioavailability (31%) but shortest duration.
Richards JR, Gordon BK, Danielson AR, Moulin AK · Gastroenterology · Apr 2026
Comprehensive review of CHS pathophysiology implicates TRPV1 receptor dysregulation and hypothalamic temperature dysregulation. Hot water bathing behavior explained by TRPV1 activation. Capsaicin cream and haloperidol identified as most evidence-supported acute treatments.
Ferber SG, Namdar D, Hen-Shoval D, et al. · Phytomedicine · Mar 2026
Review of 31 studies found mixed evidence for the entourage effect. Myrcene and linalool showed the most consistent synergistic activity with CBD in preclinical models. Clinical evidence remains limited and methodologically heterogeneous.
Hurd YL, Spriggs S, Alishayev J, et al. · Journal of Addiction Medicine · May 2026
CBD attenuated opioid withdrawal symptoms in a double-blind RCT of 60 patients, reducing anxiety, cravings, and autonomic symptoms over a 7-day protocol. Dose-dependent effects observed at 400mg and 800mg daily doses.
Showing 15 of 14,800+ indexed studies
